Time resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling

  1. Vidyasiri Vemulapalli
  2. Lily A Chylek
  3. Alison Erickson
  4. Anamarija Pfeiffer
  5. Khal-Hentz Gabriel
  6. Jonathan LaRochelle
  7. Kartik Subramanian
  8. Ruili Cao
  9. Kimberley Stegmaier
  10. Morvarid Mohseni
  11. Matthew J LaMarche
  12. Michael G Acker
  13. Peter K Sorger
  14. Steven P Gygi
  15. Stephen C Blacklow  Is a corresponding author
  1. Harvard Medical School, United States
  2. Novo Nordisk Foundation and University of Copenhagen, Denmark
  3. Broad Institute of Harvard and MIT, United States
  4. Novartis Institutes for Biomedical Research, United States

Abstract

SHP2 is a protein tyrosine phosphatase that normally potentiates intracellular signaling by growth factors, antigen receptors, and some cytokines, yet is frequently mutated in human cancer. Here, we examine the role of SHP2 in the responses of breast cancer cells to EGF by monitoring phosphoproteome dynamics when SHP2 is allosterically inhibited by SHP099. The dynamics of phosphotyrosine abundance at more than 400 tyrosine residues reveal six distinct response signatures following SHP099 treatment and washout. Remarkably, in addition to newly identified substrate sites on proteins such as occludin, ARHGAP35, and PLCγ2, another class of sites shows reduced phosphotyrosine abundance upon SHP2 inhibition. Sites of decreased phospho-abundance are enriched on proteins with two nearby phosphotyrosine residues, which can be directly protected from dephosphorylation by the paired SH2 domains of SHP2 itself. These findings highlight the distinct roles of the scaffolding and catalytic activities of SHP2 in effecting a transmembrane signaling response.

Data availability

Quantitative proteomics data have been deposited in the mass spectrometry interactive virtual environment (MassIVE) database with the accession code MSV000083702. All other data generated in this study are in the manuscript and supporting files.

The following data sets were generated

Article and author information

Author details

  1. Vidyasiri Vemulapalli

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  2. Lily A Chylek

    Systems Biology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  3. Alison Erickson

    Cell Biology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  4. Anamarija Pfeiffer

    Center for Protein Research, Novo Nordisk Foundation and University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  5. Khal-Hentz Gabriel

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  6. Jonathan LaRochelle

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  7. Kartik Subramanian

    Department of Systems Biology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6900-8882
  8. Ruili Cao

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. Kimberley Stegmaier

    Broad Institute of Harvard and MIT, Cambridge, United States
    Competing interests
    No competing interests declared.
  10. Morvarid Mohseni

    Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    Morvarid Mohseni, Novartis employee while this work was performed..
  11. Matthew J LaMarche

    Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    Matthew J LaMarche, Novartis employee while this work was performed..
  12. Michael G Acker

    Oncology, Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    Michael G Acker, Novartis employee while this work was performed..
  13. Peter K Sorger

    HMS LINCS Center, Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3364-1838
  14. Steven P Gygi

    Department of Cell Biology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  15. Stephen C Blacklow

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    For correspondence
    stephen_blacklow@hms.harvard.edu
    Competing interests
    Stephen C Blacklow, SCB receives research funding for this project from Novartis, is a member of the SAB of Erasca, Inc., is an advisor to MPM Capital, and is a consultant on unrelated projects for IFM, Scorpion Therapeutics, and Ayala Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6904-1981

Funding

Novartis Institutes for BioMedical Research

  • Vidyasiri Vemulapalli
  • Khal-Hentz Gabriel
  • Jonathan LaRochelle
  • Kimberley Stegmaier
  • Stephen C Blacklow

National Cancer Institute (R35 CA220340)

  • Stephen C Blacklow

National Heart, Lung, and Blood Institute (U54-HL127365)

  • Lily A Chylek
  • Peter K Sorger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Vemulapalli et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,405
    views
  • 488
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Vidyasiri Vemulapalli
  2. Lily A Chylek
  3. Alison Erickson
  4. Anamarija Pfeiffer
  5. Khal-Hentz Gabriel
  6. Jonathan LaRochelle
  7. Kartik Subramanian
  8. Ruili Cao
  9. Kimberley Stegmaier
  10. Morvarid Mohseni
  11. Matthew J LaMarche
  12. Michael G Acker
  13. Peter K Sorger
  14. Steven P Gygi
  15. Stephen C Blacklow
(2021)
Time resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling
eLife 10:e64251.
https://doi.org/10.7554/eLife.64251

Share this article

https://doi.org/10.7554/eLife.64251

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Birol Cabukusta, Shalom Borst Pauwels ... Jacques Neefjes
    Research Article

    Numerous lipids are heterogeneously distributed among organelles. Most lipid trafficking between organelles is achieved by a group of lipid transfer proteins (LTPs) that carry lipids using their hydrophobic cavities. The human genome encodes many intracellular LTPs responsible for lipid trafficking and the function of many LTPs in defining cellular lipid levels and distributions is unclear. Here, we created a gene knockout library targeting 90 intracellular LTPs and performed whole-cell lipidomics analysis. This analysis confirmed known lipid disturbances and identified new ones caused by the loss of LTPs. Among these, we found major sphingolipid imbalances in ORP9 and ORP11 knockout cells, two proteins of previously unknown function in sphingolipid metabolism. ORP9 and ORP11 form a heterodimer to localize at the ER-trans-Golgi membrane contact sites, where the dimer exchanges phosphatidylserine (PS) for phosphatidylinositol-4-phosphate (PI(4)P) between the two organelles. Consequently, loss of either protein causes phospholipid imbalances in the Golgi apparatus that result in lowered sphingomyelin synthesis at this organelle. Overall, our LTP knockout library toolbox identifies various proteins in control of cellular lipid levels, including the ORP9-ORP11 heterodimer, which exchanges PS and PI(4)P at the ER-Golgi membrane contact site as a critical step in sphingomyelin synthesis in the Golgi apparatus.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Kien Xuan Ngo, Huong T Vu ... Taro Uyeda
    Research Article

    The mechanism underlying the preferential and cooperative binding of cofilin and the expansion of clusters toward the pointed-end side of actin filaments remains poorly understood. To address this, we conducted a principal component analysis based on available filamentous actin (F-actin) and C-actin (cofilins were excluded from cofilactin) structures and compared to monomeric G-actin. The results strongly suggest that C-actin, rather than F-ADP-actin, represented the favourable structure for binding preference of cofilin. High-speed atomic force microscopy explored that the shortened bare half helix adjacent to the cofilin clusters on the pointed end side included fewer actin protomers than normal helices. The mean axial distance (MAD) between two adjacent actin protomers along the same long-pitch strand within shortened bare half helices was longer (5.0–6.3 nm) than the MAD within typical helices (4.3–5.6 nm). The inhibition of torsional motion during helical twisting, achieved through stronger attachment to the lipid membrane, led to more pronounced inhibition of cofilin binding and cluster formation than the presence of inorganic phosphate (Pi) in solution. F-ADP-actin exhibited more naturally supertwisted half helices than F-ADP.Pi-actin, explaining how Pi inhibits cofilin binding to F-actin with variable helical twists. We propose that protomers within the shorter bare helical twists, either influenced by thermal fluctuation or induced allosterically by cofilin clusters, exhibit characteristics of C-actin-like structures with an elongated MAD, leading to preferential and cooperative binding of cofilin.